136 related articles for article (PubMed ID: 23152018)
1. [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Chiba A; Shimizu S; Yoshida A; Inaba M; Matsuura H; Ino H; Suganuma N; Inari H; Yamanaka T; Kuroda K; Mukaibashi T; Matsuo A; Kojima I
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1675-9. PubMed ID: 23152018
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
7. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
8. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
[TBL] [Abstract][Full Text] [Related]
9. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Sutherland S; Ashley S; Miles D; Chan S; Wardley A; Davidson N; Bhatti R; Shehata M; Nouras H; Camburn T; Johnston SR
Br J Cancer; 2010 Mar; 102(6):995-1002. PubMed ID: 20179708
[TBL] [Abstract][Full Text] [Related]
10. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R
Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Bachelot T; Romieu G; Campone M; Diéras V; Cropet C; Dalenc F; Jimenez M; Le Rhun E; Pierga JY; Gonçalves A; Leheurteur M; Domont J; Gutierrez M; Curé H; Ferrero JM; Labbe-Devilliers C
Lancet Oncol; 2013 Jan; 14(1):64-71. PubMed ID: 23122784
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Cameron D; Casey M; Oliva C; Newstat B; Imwalle B; Geyer CE
Oncologist; 2010; 15(9):924-34. PubMed ID: 20736298
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Geyer CE; Forster J; Lindquist D; Chan S; Romieu CG; Pienkowski T; Jagiello-Gruszfeld A; Crown J; Chan A; Kaufman B; Skarlos D; Campone M; Davidson N; Berger M; Oliva C; Rubin SD; Stein S; Cameron D
N Engl J Med; 2006 Dec; 355(26):2733-43. PubMed ID: 17192538
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.
Crivellari D; Spazzapan S; Lombardi D; Militello L; Torrisi E; Russo AE; Sorio R; Talamini R; Miolo G; Carli P; Veronesi A
Tumori; 2012; 98(1):33-8. PubMed ID: 22495699
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
[TBL] [Abstract][Full Text] [Related]
18. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Han SW; Cha Y; Paquet A; Huang W; Weidler J; Lie Y; Sherwood T; Bates M; Haddad M; Park IH; Oh DY; Lee KS; Im SA; Bang YJ; Ro J; Kim TY
PLoS One; 2012; 7(7):e39943. PubMed ID: 22848366
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
20. Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.
Carli P; Militello L; Miolo GM; Quitadamo D; Lombardi D; Torrisi E; Scalone S; Crivellari D; Spazzapan S
Tumori; 2014; 100(6):605-11. PubMed ID: 25688493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
